We are developing a lisuride transdermal patch to be placed on the skin that is intended to deliver continuous, stable levels of dopaminergic stimulation for up to seven days. NeuroBiotec has completed a clinical trial of lisuride transdermal patch in advanced Parkinson’s disease in 329 patients. The lisuride transdermal patch is currently undergoing clinical development in Europe for Parkinson’s disease. We expect to initiate U.S. clinical trials of lisuride transdermal patch in 2006.